Drugs / ACE1831
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05653271 | Jan 2023 → Mar 2026 | Burkitt lymphoma, follicular lymphoma, high grade B-cell lymphoma, marginal zone lymphoma +1 | Acepodia Biotech, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07061938 | Jan 2026 → Sep 2029 expected | immunoglobulin G4-related sclerosing disease | Acepodia Biotech, Inc. | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07314567 | Jan 2026 → Oct 2027 expected | systemic lupus erythematosus | Tongji Hospital | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-06-18 | Acepodia Biotech, Inc. | Results Acepodia Completes Phase 1 Clinical Study Report for ACE1831 in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma acepodia.com ↗
Based on the available data, ACE1831 demonstrated a safety and tolerability profile consistent with expectations for a Phase 1 study. |
| 2025-12-04 | Acepodia Biotech, Inc. | Regulatory Acepodia Announces NMPA Approval of ACE1831 for IgG4-RD Phase Ib/IIa Clinical Trial,Marking a Major Step Forward in Its Global Multi-Country Development Strategy acepodia.com ↗
Acepodia Inc. (6976.TT) today announced that its lead allogeneic cell therapy candidate ACE1831 has officially received approval from China’s National Medical Products Administration (NMPA) to initiate a Phase Ib/IIa clinical trial for IgG4-related disease (IgG4-RD). |
| 2025-10-07 | Acepodia Biotech, Inc. | Regulatory Acepodia Announces IND Clearance by Japan PMDA for ACE1831 in the Treatment of IgG4-Related Disease; China IND Review in Progress acepodia.com ↗
Acepodia (6976: TT) today announced that the Investigational New Drug (IND) application for ACE1831 in the treatment of IgG4-related disease (IgG4-RD) has been cleared by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). |
| 2022-04-19 | Acepodia Biotech, Inc. | Results Acepodia Presents Preclinical Data on its gamma delta T cell Therapy Candidate ACE1831 at 2022 AACR Meeting acepodia.com ↗
ACE 1831 showed superior in vitro and in vivo potency against B cell lymphoma. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-18 | Acepodia Biotech, Inc. | Acepodia Completes Phase 1 Clinical Study Report for ACE1831 in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma acepodia.com ↗ |
| 2025-12-04 | Acepodia Biotech, Inc. | Acepodia Announces NMPA Approval of ACE1831 for IgG4-RD Phase Ib/IIa Clinical Trial,Marking a Major Step Forward in Its Global Multi-Country Development Strategy acepodia.com ↗ |
| 2025-10-07 | Acepodia Biotech, Inc. | Acepodia Announces IND Clearance by Japan PMDA for ACE1831 in the Treatment of IgG4-Related Disease; China IND Review in Progress acepodia.com ↗ |
| 2022-04-19 | Acepodia Biotech, Inc. | Acepodia Presents Preclinical Data on its gamma delta T cell Therapy Candidate ACE1831 at 2022 AACR Meeting acepodia.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACE1831 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07314567 ↗ |
| Modality | Cell therapy | “Allogeneic gamma delta T (gdT) cell therapy” NCT05653271 ↗ |